BioLine Rx (BioLine Rx) Receivables Turnover : 13.41 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioLine Rx's Revenue for the three months ended in Dec. 2023 was $4.80 Mil. BioLine Rx's average Accounts Receivable for the three months ended in Dec. 2023 was $0.36 Mil. Hence, BioLine Rx's Receivables Turnover for the three months ended in Dec. 2023 was 13.41.

BioLine Rx Receivables Turnover Historical Data

The historical data trend for BioLine Rx's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Receivables Turnover Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

13.41

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	13.41

Competitive Comparison of BioLine Rx's Receivables Turnover

For the Biotechnology subindustry, BioLine Rx's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Receivables Turnover falls into.

BioLine Rx Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

BioLine Rx's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	4.8	/ (	(0	+	0.358)	/	1 )
=	4.8	/	0.358
=	13.41

BioLine Rx's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	4.8	/ (	(0	+	0.358)	/	1 )
=	4.8	/	0.358
=	13.41

BioLine Rx (NAS:BLRX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

BioLine Rx Receivables Turnover Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.